UKERi33Q-R2-006
The cell line is not validated yet.
UKERi009-A
General
Cell Line |
|
hPSCreg name | UKERi009-A |
Cite as: | UKERi009-A (RRID:CVCL_C1JQ) |
Alternative name(s) |
UKERi33Q-R2-006
|
Cell line type | Human induced pluripotent stem cell (hiPSC) |
Similar lines | No similar lines found. |
Last update | 16th April 2022 |
User feedback | |
Provider |
|
Generator |
Universitätsklinikum Erlangen (UKER)
Contact:
Universitätsklinikum Erlangen (UKER) |
Owner | Universitätsklinikum Erlangen (UKER) |
Distributors | |
Derivation country | Germany |
External Databases |
|
BioSamples | SAMEA13024890 |
Cellosaurus | CVCL_C1JQ |
Wikidata | Q114313170 |
General Information |
|
* Is the cell line readily obtainable for third parties? |
No |
Donor Information
General Donor Information |
|
Sex | female |
Age of donor (at collection) | 45-49 |
Ethnicity | caucasian |
Phenotype and Disease related information (Donor) |
|
Diseases | No disease was diagnosed.
|
Karyotyping (Donor) |
|
Has the donor karyotype been analysed? |
Yes
46XX
|
External Databases (Donor) |
|
BioSamples | SAMEA13024891 |
Ethics
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
Was the consent voluntarily given? | Yes |
Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
Confirm that consent was obtained by a qualified professional | Yes |
Has the donor agreed to be re-contacted? | Yes |
Has the donor been informed about how her/his data will be protected? | Yes |
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
How may genetic information associated with the cell line be accessed? | Controlled Access |
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
Name of accrediting authority involved? | Research Ethics Committee Friedrich-Alexander University Erlangen-Nürnberg |
Approval number | |
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
Source cell type |
Any skin fibroblast that is part of some dermis.
|
Source cell origin |
The skin or integument covering the arm.
Synonyms
|
Age of donor (at collection) | 45-49 |
Reprogramming method |
|
Vector type | Integrating |
Vector | Virus (Retrovirus) |
Is the used vector excisable? |
Unknown |
Absence of reprogramming vector(s)? |
Unknown |
Reprogramming vectors silenced? | |
Vector free reprogramming |
|
Other |
|
Derived under xeno-free conditions |
Unknown |
Derived under GMP? |
Unknown |
Available as clinical grade? |
Unknown |
Culture Conditions
Feeder cells |
No |
Passage method | Enzymatically |
CO2 Concentration | 5 % |
Medium |
mTeSR™ Plus
|
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
TRA 1-60 |
Yes |
|
||||
POU5F1 (OCT-4) |
Yes |
|
||||
NANOG |
Yes |
|
Differentiation Potency
In vitro directed differentiation
In vitro directed differentiation
Microbiology / Virus Screening |
|
Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
46XX
Passage number: 5
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
Login to share your feedback, experiences or results with the research community.